Tag: Adverse events

While prucalopride can effectively relieve chronic idiopathic constipation in many adults, as many as 5% of patients in clinical trials discontinued treatment due to adverse reactions such as nausea, headache, abdominal pain, or diarrhea. This underscores the importance of understanding what are the dangers of prucalopride and the serious, albeit rare, risks associated with its use.

In transplant recipients and cancer patients, the incidence of mTOR inhibitor-associated stomatitis (mIAS) can be as high as 60% [1.2.3]. Understanding 'What are the side effects of mTOR inhibitors?' is crucial for managing these powerful drugs used in oncology and immunosuppression [1.2.3, 1.7.4].

A 2011 Cochrane review found that people on biologics were slightly more likely to experience serious infections compared to those on a placebo, highlighting the reality that the question, "Do biologics have bad side effects?", requires a nuanced answer. These advanced medications, derived from living organisms, target specific parts of the immune system, leading to both significant therapeutic benefits and potential complications.

Manufacturer Allergan discontinued Lumigan (bimatoprost ophthalmic solution) 0.03% in 2012, replacing it with a 0.01% formulation that provided comparable efficacy and a better safety profile. The change aimed to offer patients a more tolerable treatment option, not due to safety concerns with the original formulation.

According to clinical trial data, the most common adverse reactions reported in at least 10% of patients treated with nipocalimab breakthrough therapy designation BTD were respiratory tract infection, peripheral edema, and muscle spasms. This FcRn inhibitor is under evaluation for several autoimmune and alloimmune conditions, making a review of its safety profile essential.

Reports from early in the COVID-19 pandemic indicated that remdesivir therapy was associated with heart rate irregularities, and researchers have since identified potential cardiovascular risks. The question of whether **does remdesivir cause heart problems** is complex, with data from case reports suggesting a link, particularly to bradycardia, while larger controlled trials have shown less evidence of widespread, severe cardiac events.

Following reports of serious adverse reactions, particularly concerning neurological function, European regulatory agencies reviewed the safety of trimetazidine, highlighting significant long-term risks. These regulatory changes underscore the critical importance of understanding **what are the long-term side effects of trimetazidine** for patients and healthcare providers alike.

Based on pivotal clinical trials, approximately 8% of people taking Leqvio experienced an injection site reaction, the most common side effect. While other adverse events occurred, the overall rate of side effects was comparable to placebo, making the question 'what percentage of people have side effects from Leqvio?' crucial for patient understanding.

In clinical trials, hand-foot syndrome (HFS) was reported to occur more often with capecitabine than with intravenous 5-FU, making it a very common and distinctive side effect. While diarrhea is also very common, the combination of these two adverse events often defines a patient's experience with capecitabine.

In clinical studies, the percentage of people experiencing side effects from tamsulosin can vary, with some long-term studies reporting that up to 26% of patients had possibly drug-related adverse events. However, many of these side effects are mild, and the overall discontinuation rate is low.